Renal Ewing sarcoma treated with apatinib

Renal Ewing sarcoma (RES) is an extremely rare disease. The standard treatment for this disease is lacking, and clinical experience needs to be accumulated. Here, we report a case of RES that rapidly developed to metastatic disease and was refractory to radiotherapy and chemotherapy; however, the case obtained a partial response based on Choi criteria by orally taking antiangiogenic drug apatinib. Our case suggests that apatinib may be a therapeutic option for RES. Correspondence to Ji-Yan Liu, MD, PhD, The State Key Laboratory of Biotherapy, Department of Medical Oncology, West China Medical School, Cancer Center, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu 610041, Sichuan Province, China Tel: +86 288 542 3262; fax: +86 288 542 3609; e-mail: liujiyan1972@163.com Received December 7, 2017 Accepted March 15, 2018 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

https://ift.tt/2wVeQBP